Homodimeric Minimal Factor H: <i>In Vivo</i> Tracking and Extended Dosing Studies in Factor H Deficient Mice.

ABSTRACT: C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway (AP) of complement and treatment options remain inadequate. Factor H (FH) is a potent regulator of the AP. An in-depth analysis of FH-related protein dimerised minimal (mini)-FH constructs has recently been published. This analysis showed that addition of a dimerisation module to mini-FH not only increased serum half-life but also improved complement regulatory function, thus providing a potential treatment option for C3G. Herein, we describe the production of a murine version of homodimeric mini-FH [mHDM-FH (mFH^{1-5^18-20^R1-2})], developed to reduce the risk of anti-drug antibody formation during long-term experiments in murine models of C3G and other complement-driven pathologies. Our analysis o

SUBMITTER: Kamala O 

PROVIDER: S-EPMC8696033 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature